Villanueva OGS, Martínez SI, Parral PJM, Cázares MHM

Language: Spanish
References: 12
Page: 144-147
PDF size: 153.89 Kb.

ABSTRACT

Acute generalized exanthematous pustulosis, although rare and with low mortality, produces systemic involvement in up to 20% of patients; it is caused by drugs in up to 93% of the cases, of which a quarter are antibiotics. It presents with non-follicular sterile pustules that subside two weeks after suspending the causal agent, but can cause systemic alterations such as fever, leukocytosis, neutrophilia and hypocalcemia. The diagnosis is clinical and is complemented by laboratory studies and biopsy. It is treated by eliminating the offending drug and topical steroids. Ceftriaxone is the cause of this condition in 9.3% of cases in Asia, little reported in Latin America and Mexico. We present the case of a 68-year-old female with a history of scleroderma, hypothyroidism, and celiac disease. She began his current illness on March 2022, presenting a febrile episode, accompanied by malaise, nausea, asthenia, adynamia, dysuria, polaquiuria, and bladder urgency, presenting a general urine test with data of infection, starting treatment with ceftriaxone, after four doses she presented generalized dermatosis, characterized by erythema, mild edema in the face, arms and chest, on the legs she presented post-inflammatory lamellar scale, on the thighs multiple non-follicular pustules. Also leukocytosis with neutrophilia, so ceftriaxone was suspended, with good progression.

REFERENCES

1. Guvenir H, Arikoglu T, Vezir E y Misirlioglu ED, Clinical phenotypesof severe cutaneous drug hypersensitivity reactions, CurrPharm Des 2019; 25(36):3840-54.GUADALUPE SARAHÍ VILLANUEVA OLGUÍN Y COLS. POSTULOSIS EXANTEMÁTICA AGUDA

2. Mustafa SS, Ostrov D y Yerly D, Severe cutaneous adverse drugreactions: presentation, risk factors, and management, Curr AllergyAsthma Rep 2018; 18(4):26.

3. Oh DAQ, Yeo YW, Choo KJL, Pang SM, Oh CC y Lee HY, Acutegeneralized exanthematous pustulosis: epidemiology, clinicalcourse, and treatment outcomes of patients treated in an Asianacademic medical center, jaad Int 2021; 3:1-6.

4. Zhang J, Lei Z, Xu C, Zhao J y Kang X, Current perspectiveson severe drug eruption, Clin Rev Allergy Immunol 2021;61(3):282-98.

5. Feldmeyer L, Heidemeyer K y Yawalkar N, Acute generalizedexanthematous pustulosis: pathogenesis, genetic background,clinical variants and therapy, Int J Mol Sci 2016; 17(8):1214.

6. Szatkowski J y Schwartz RA, Acute generalized exanthematouspustulosis (agep): a review and update, J Am Acad Dermatol2015; 73(5):843-8.

7. Kang SY, Park SY, Kim JH, Lee SM y Lee SP, Pustulosis exantemáticageneralizada aguda inducida por la vacuna covid-19,Korean J Intern Med 2021; 36(6):1537-8.

8. Vallejo-Yagüe E, Martínez-De la Torre A, Mohamad OS, Sabu Sy Burden AM, Drug triggers and clinic of acute generalized exanthematouspustulosis (agep): a literature case series of 297patients, J Clin Med 2022; 11(2):397.

9. Sussman M, Napodano A, Huang S, Are A, Hsu S y MotaparthiK, Pustular psoriasis and acute generalized exanthematous pustulosis,Medicina (Kaunas) 2021; 57(10):1004.

10. Phillips EJ, Bigliardi P, Bircher AJ et al., Controversies in drugallergy: testing for delayed reactions, J Allergy Clin Immunol2019; 143(1):66-73.

11. Guevara-Gutiérrez E, Uribe-Jiménez E, Díaz-Canchola M yTlacuilo-Parra A, Acute generalized exanthematous pustulosis:report of 12 cases and literature review, The International Societyof Dermatology 2009; 48(1):253-8.

12. Álvaro-Vázquez J, Bernanbé-Del Río C, Maya-Aranda SE y Espinosa-Tavitas M, Pustulosis exantemática generalizada agudainducida por ceftriaxona, Med Cutan Iber Lat Am 2016; 44(3):216-20.